title: Parenteral iron compounds: potent oxidants but mainstays of anemia management in chronic renal disease.
abstract: Ferric iron (Fe)-carbohydrate complexes are widely used for treating Fe deficiency in patients who are unable to meet their Fe requirements with oral supplements. Intravenous Fe generally is well tolerated and effective in correcting Fe-deficient states. However, the complexing of Fe to carbohydrate polymers does not block its potent pro-oxidant effects; systemic free radical generation and, possibly, tissue damage may result. The purpose of this review is to (1) underscore the capacity of currently used parenteral Fe formulations to induce oxidative stress, (2) compare the severity of these oxidant reactions with those that result from unshielded Fe salts and with each other, and (3) speculate as to the potential of these agents to induce acute renal cell injury and augment systemic inflammatory responses. The experimental data that are reviewed should not be extrapolated to the clinical setting or be used for clinical decision making. Rather, it is hoped that the information provided herein may have utility for clinical hypothesis generation and, hence, future clinical studies. By so doing, a better understanding of Fe's potential protean effects on patients with renal disease may result.
authors: Fred Hutchinson Cancer Research Center, Department of Medicine, University of Washington, Seattle, Washington 98109, USA. dzager@fhcrc.org
authors: Richard A
authors: RA
authors: Zager
mesh_terms: D058186:Acute Kidney Injury / Q000139:chemically induced* / Q000378:metabolism; D000255:Adenosine Triphosphate / Q000378:metabolism; D018798:Anemia, Iron-Deficiency / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D000818:Animals; D042783:Endothelial Cells / Q000187:drug effects / Q000378:metabolism; D005290:Ferric Compounds / Q000633:toxicity; D000077605:Ferric Oxide, Saccharated; D005937:Glucaric Acid; D006397:Hematinics / Q000008:administration & dosage / Q000633:toxicity*; D006801:Humans; D007249:Inflammation / Q000139:chemically induced* / Q000378:metabolism; D007262:Infusions, Intravenous; D058085:Iron Compounds / Q000008:administration & dosage / Q000633:toxicity*; D007505:Iron-Dextran Complex / Q000633:toxicity; D007672:Kidney Cortex / Q000187:drug effects / Q000378:metabolism; D007687:Kidney Tubules, Proximal / Q000187:drug effects / Q000378:metabolism; D015227:Lipid Peroxidation / Q000187:drug effects; D008928:Mitochondria / Q000187:drug effects / Q000378:metabolism; D018384:Oxidative Stress / Q000187:drug effects*; D006435:Renal Dialysis; D051436:Renal Insufficiency, Chronic / Q000150:complications* / Q000188:drug therapy / Q000378:metabolism / Q000628:therapy; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
chemical_list: D005290:Ferric Compounds; D006397:Hematinics; D058085:Iron Compounds; D014409:Tumor Necrosis Factor-alpha; D000255:Adenosine Triphosphate; D007505:Iron-Dextran Complex; D000077605:Ferric Oxide, Saccharated; D005937:Glucaric Acid; C035552:ferric gluconate